IL-STERN-PINBALL,-INC.
Stern Pinball, Inc., announces a new state-of-the-art The Mandalorian pinball Topper accessory compatible with the Pro, Premium, and Limited Edition (LE) models of The Mandalorian.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221019005032/en/
The Mandalorian is a critically acclaimed, Emmy-winning hit original series, streaming exclusively through Disney+. The series follows the travails of a lone gunfighter in the outer reaches of the galaxy, teaming up with key allies and protecting Grogu, while battling dangerous enemies and forces across their journey.
The Mandalorian-inspired Topper accessory introduces exclusive new gameplay features while transporting the player inside the cockpit of the Razor Crest™, using a 3D holographic display in vivid color. New gameplay features include Mandalorian Madness™, a mini wizard mode, and Beskar™ Bonanza, a progressive mode that awards all upgrades in the Foundry™.
The Mandalorian-inspired Topper leverages the Stern Insider Connected™ platform to enhance the gameplay experience. In addition to a player’s username and icon, the topper displays a player’s lifetime Encounter upper mini playfield accuracy percentage, plus lifetime Beskar™ collected for all games played while logged in to their Insider Connected player account. Players can also earn exclusive Insider Connected Achievements. The Topper comes equipped with Competition Mode functionality, displaying all player scores with the current high score being highlighted.
“The Mandalorian-inspired Topper is a game changer for The Mandalorian pinball playing experience,” said Gary Stern, Chairman and CEO of Stern Pinball, Inc. “This innovative and interactive topper will keep players connected with stunning visuals and all new features never achieved through a pinball topper accessory before.”
Pricing and Availability:
Manufacturer’s Suggested Retail Price: $US 1,999
MSRP for sales to USA end-users, before any VAT, GST, Sales Tax, Duties, or other taxes.
The Mandalorian-inspired pinball machines and accessories are available now through authorized Stern Pinball distributors and dealers around the world.
About Stern Pinball, Inc.
Stern Pinball, Inc. is a global lifestyle brand based on the iconic and outrageously fun modern American game of pinball. Headquartered minutes from Chicago’s O’Hare International Airport in the heart of North America, the company creates, designs, engineers, manufactures, markets, and distributes a full line of technologically advanced terrestrial and digital pinball games, parts, accessories, and merchandise. Stern Pinball serves digital, consumer, commercial, and corporate markets around the globe.
Recent Stern Pinball titles include James Bond, Rush, Godzilla, The Mandalorian, Led Zeppelin, Teenage Mutant Ninja Turtles, Stranger Things, Elvira’s House of Horrors, Jurassic Park, Black Knight: Sword of Rage, The Munsters, The Beatles, Iron Maiden, Aerosmith, Ghostbusters, KISS, Metallica, Game of Thrones, The Walking Dead, Star Trek, AC/DC, and Batman. A broad range of players enjoy Stern Pinball’s games from professional pinball players who compete in high-stakes competitions around the globe to novice players who are discovering the allure of the silver ball for the first time. To join the fun and learn more, please visit www.sternpinball.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221019005032/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ImmunAbs Announces FDA Phase 2 IND Approval of IM-101, a Novel Complement C5 Inhibitor, for Treatment of Myasthenia Gravis2.6.2025 13:00:00 CEST | Press release
ImmunAbs Inc., a clinical-stage biotech specializing in developing antibody therapeutics, today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial evaluating the safety and efficacy of IM-101, a novel complement C5 inhibitor, for the treatment of Myasthenia Gravis. The forthcoming multicenter, randomized, double-blind, placebo-controlled study will enroll up to 90 patients to evaluate the effectiveness and safety of monthly IM-101 dosing in relieving complement-induced symptoms in MG. “This IND approval is pivotal for us as it brings us one step closer to delivering a transformative therapy for patients with autoimmune disorders”, said Dr. Dongjo Kim, the CEO of ImmunAbs, “we believe IM-101 has the potential to deliver deeper therapeutic responses and more durable remissions in patients who have failed to achieve sustained remission with current approved treatment.” About Myasthenia Gravis
Lenovo and Bellevue University Team Up to Offer Supply Chain and Logistics Education to Deliver “Smarter Technology for All”2.6.2025 13:00:00 CEST | Press release
Learners will have access to Lenovo’s globally recognized supply chain expertise through real-world case studies and subject matter experts. Lenovo, the global technology powerhouse, recognized in the top 10 in the Gartner Supply Chain Top 25, and Bellevue University, one of the nation’s top online universities, are teaming up to develop the next generation of supply chain professionals. “We believe that bringing real-world Global Supply Chain experience and learning directly into an education curriculum is precisely the optimal way to upskill the workforce of the future,” said Ben Massie, Vice President, Global Supply Chain, Lenovo. “Teaming up with Bellevue allows us to attract the right talent using the right technology and deliver on our mission to make ‘smarter technology for all’ a reality.” As a preferred higher education institution tapped to team up with Lenovo to offer supply chain short-term learning, Bellevue will leverage the breadth and depth of Lenovo’s supply chain expe
Lifezone Metals Files Initial Assessment for the Kabanga Nickel Project in Tanzania2.6.2025 12:30:00 CEST | Press release
Vertically Integrated Plan includes Hydrometallurgical Refinery at Kahama $2.37 Billion After-Tax NPV (8%) and 22.9% After-Tax IRR at $8.49 per Pound Nickel Price Initial Assessment Proposes a 22-Year Mine Plan at Average 2.39% Nickel Equivalent Grade Webcast with Technical Leadership Team at 10 AM ET on Tuesday, June 3, 2025 Lifezone Metals Limited’s (NYSE: LZM) Chief Executive Officer, Chris Showalter, and Chief Operating Officer, Gerick Mouton, announce today the results from the Initial Assessment for its flagship Kabanga Nickel Project in northwest Tanzania. The Initial Assessment evaluates a vertically integrated mining, processing and refining operation, commencing with a high-grade nickel sulfide underground mine and concentrator at the Kabanga site, followed five years later by a hydrometallurgical refinery at Kahama. The study covers the Main, MNB, Kima, North, and Tembo zones and is based on the December 2024 Mineral Resource Update (refer to Lifezone’s December 5, 2024 news
Corpay Cross-Border Named an Official Partner of Real Madrid C.F.2.6.2025 12:00:00 CEST | Press release
Providing access to currency risk management and cross-border payments solutions Corpay, Inc.*, (NYSE: CPAY) a global leader in corporate payments, is pleased to announce that Corpay’s Cross-Border business has entered into an agreement with Real Madrid C.F. to become an Official Partner. Through this partnership, Real Madrid will be able to gain access to and utilise Corpay Cross Border’s innovative solutions to help mitigate foreign exchange exposure from their day-to-day business needs. "The Corpay Cross-Border team is elated to be named an Official Partner of Real Madrid, one of the world’s most widely recognized and followed sports franchises," said Brad Loder, Chief Marketing Officer, Corpay Cross-Border Solutions. “With our strong focus on growing the Corpay brand, as well as our currency risk management business, we are excited to partner with one of the most successful football clubs in the world.” About Corpay Corpay, Inc. (NYSE: CPAY) is a global S&P500 corporate payments co
BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 20252.6.2025 12:00:00 CEST | Press release
Preliminary results highlight anti-tumor activity and favorable safety profiles of both B7-H4-targeting ADC and CDK2 inhibitorData underscore strength of emerging breast cancer pipeline as part of BeOne’s global transformation with next wave of innovation BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, announced new clinical data from its emerging breast cancer pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Poster presentations feature preliminary results of the dose escalation studies of two investigational molecules: BG-C9074, a novel B7-H4-targeting antibody-drug conjugate (ADC) in patients with advanced solid tumors, including breast cancer, and BG-68501, a cyclin-dependent kinase-2 inhibitor (CDK2i), in HR+/HER2- breast cancer patients with prior CDK4/6i exposure. “Presenting the first clinical data for two novel breast cancer candidates at ASCO 2025 marks a pivotal moment for BeOne,” said Mark Lanas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom